A professional sheds light on the pros and cons of a drug recently released by Anvisa for the treatment of obesity


According to the doctor, obesity is a disease that can significantly increase the risk of other pathologies.

Semaglutide was recently released by Anvisa
© Playback/PixabaySemaglutide was recently released by Anvisa

THE obesity It is one of the biggest diseases facing mankind. The number of obese people is increasing dramatically in the world, and in Brazil about 20 million people are overweight. In this area, cardiologist and pacemaker specialist Dr. Roberto Yano commented on the release of Anvisaabout the new drug “Wegovy” (semaglutide 2.4 mg), which has the same active ingredient as the already known Ozempic, last Monday. The difference, according to the decision, is that now this new drug is specific for the treatment of obesity. But it has risks if not prescribed correctly, so it’s always good to remember: Semaglutide should never be used without a prescription.

“This drug is able to promote up to 17% reduction in body weight in patients. That is, a person weighing 100 kg can lose 83 kg. Of course, this is an average of those receiving the appropriate treatment. Semaglutide works in several ways: it reduces the glucose blood, stimulates insulin secretion, reduces glucagon secretion (…) There is also a feeling that he is more full after meals, thus reducing body weight and body fat”started.

The person using semaglutide eventually loses their preference for eating higher calorie and fatty foods. There may also be a favorable effect on blood vessels, mitigating the development of atherosclerotic plaques“, he completed. Thus, the main effect of this drug is to decrease the appetite and give the feeling of satiety“, concluded Yano.

The professional pointed out the side effects. According to the doctor, the drug can cause effects so severe that the person may need to stop treatment sooner. “The most common effects are hypoglycaemia, especially if the person is already using certain medications for diabetes, this can cause nausea, diarrhea (…) In addition, it can cause dizziness, fatigue, pain abs and abdominal extension. The question of price remains. To give you an idea, in the United States, where semaglutide is already sold, the treatment costs around 7,000 reais per month. In Brazil, we still don’t have an estimate of what the value will be. And just to clarify a little more, this drug is injectable and applied once a week“, said.

Download the Bolavip app and follow all your favorite team’s information in real timehttps://bit.ly/BV-app22

Add Comment